Contribute Try STAT+ Today

Federal authorities alleged that Teva Pharmaceuticals (TEVA) donated hundreds of millions of dollars to a pair of foundations, but the payments were actually kickbacks to Medicare patients and designed to cover their out-of-pocket costs for a pricey medicine.

In a lawsuit filed in federal court in Boston, the Department of Justice accused the drug maker of using the charities — the Chronic Disease Fund and The Assistance Fund — to ensure that, from 2006 through 2015, Medicare patients did not have to make a co-payment or deductible for the Copaxone multiple sclerosis drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.